1208552-99-1 Usage
Uses
Used in Pharmaceutical Research:
(S)-2-(4-Chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide is used as a potential therapeutic agent for its analgesic and anti-inflammatory properties, which may contribute to the development of new medications for pain relief and the treatment of inflammatory conditions.
Used in Drug Development:
In the drug development industry, (S)-2-(4-Chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide is utilized as a lead compound for the creation of novel pharmaceuticals. Its structure and bioactivity make it a candidate for further optimization and testing to potentially treat various diseases and disorders.
Used in Chemical Synthesis:
(S)-2-(4-Chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide may also serve as a key intermediate in the synthesis of other complex organic molecules, particularly in the fields of medicinal chemistry and material science, where its unique structure could be exploited to create new compounds with specific applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1208552-99-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,8,5,5 and 2 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1208552-99:
(9*1)+(8*2)+(7*0)+(6*8)+(5*5)+(4*5)+(3*2)+(2*9)+(1*9)=151
151 % 10 = 1
So 1208552-99-1 is a valid CAS Registry Number.
1208552-99-1Relevant articles and documents
The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators
Wang, Yingcai,Jiao, Xianyun,Kayser, Frank,Liu, Jiwen,Wang, Zhongyu,Wanska, Malgorzata,Greenberg, Joanne,Weiszmann, Jennifer,Ge, Hongfei,Tian, Hui,Wong, Simon,Schwandner, Ralf,Lee, Taeweon,Li, Yang
scheme or table, p. 493 - 498 (2010/04/26)
Free fatty acid receptor 2 (FFA2) is a G-protein coupled receptor for which only short-chain fatty acids (SCFAs) have been reported as endogenous ligands. We describe the discovery and optimization of phenylacetamides as allosteric agonists of FFA2. These novel ligands can suppress adipocyte lipolysis in vitro and reduce plasma FFA levels in vivo, suggesting that these allosteric modulators can serve as pharmacological tools for exploring the potential function of FFA2 in various disease conditions.